meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced OC (mOC) - 2nd line (L2)
3
immune chekpoint inhibitors
anti-PD-(L)1
avelumab based treatment
avelumab alone
avelumab plus pegylated liposomal doxorubicin
Immune checkpoint association
nivolumab plus ipilimumab
versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs anthracyclines
vs doxorubicin
vs pegylated liposomal doxorubicin
vs immune chekpoint inhibitors
vs anti-PD-(L)1
vs nivolumab based treatment
vs nivolumab alone
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
Evidence gap map
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
Immune checkpoint association
nivolumab plus ipilimumab
Comparator:
vs nivolumab alone;
Risk of bias:
low;
some concerns;
high;
NA;